Glenmark obtains FDA nod for generic Brovana
Arformoterol tartrate inhalation solution is Glenmark’s first nebulizer approval.
Glenmark has received the Food and Drug Administration’s stamp of approval for arformoterol tartrate inhalation solution 15 mcg/2 mL in unit-dose vials.
The product is a generic of Sunovion’s Brovana and the company’s first nebulizer approval.
Glenmark’s generic product will be manufactured in Monroe, N.C.